These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 24462818

  • 21. Platinum compounds in children with cancer: toxicity and clinical management.
    Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, Pierri F, Riccardi R.
    Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
    [Abstract] [Full Text] [Related]

  • 22. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 23. Regulation of DNA repair gene expression in human cancer cell lines.
    McGurk CJ, Cummings M, Köberle B, Hartley JA, Oliver RT, Masters JR.
    J Cell Biochem; 2006 Apr 01; 97(5):1121-36. PubMed ID: 16315315
    [Abstract] [Full Text] [Related]

  • 24. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT, Vaisman A, Chaney SG, Sancar A.
    Cancer Res; 1999 Aug 15; 59(16):3968-71. PubMed ID: 10463593
    [Abstract] [Full Text] [Related]

  • 25. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T, Vance R, Puneky L, Khansur T.
    Gynecol Oncol; 1994 Dec 15; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [Abstract] [Full Text] [Related]

  • 26. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 15; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 27. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J.
    Cancer; 2008 Jun 15; 112(12):2710-9. PubMed ID: 18481809
    [Abstract] [Full Text] [Related]

  • 28. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov 15; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 29. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P, Labonte MJ, Lenz HJ.
    Clin Colorectal Cancer; 2011 Sep 15; 10(3):157-64. PubMed ID: 21855036
    [Abstract] [Full Text] [Related]

  • 30. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R.
    Anticancer Res; 2014 Jan 15; 34(1):393-9. PubMed ID: 24403493
    [Abstract] [Full Text] [Related]

  • 31. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM.
    Semin Oncol; 2004 Dec 15; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [Abstract] [Full Text] [Related]

  • 32. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M.
    J Clin Oncol; 2004 Oct 01; 22(19):3852-9. PubMed ID: 15326195
    [Abstract] [Full Text] [Related]

  • 33. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 34. Advanced ovarian cancer. Carboplatin versus cisplatin.
    Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB.
    Ann Oncol; 1993 May 01; 4 Suppl 4():41-8. PubMed ID: 8312200
    [Abstract] [Full Text] [Related]

  • 35. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
    Ho GY, Woodward N, Coward JI.
    Crit Rev Oncol Hematol; 2016 Jun 01; 102():37-46. PubMed ID: 27105947
    [Abstract] [Full Text] [Related]

  • 36. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
    Tiseo M, Boni L, Ardizzoni A.
    J Clin Oncol; 2005 Sep 01; 23(25):6276-7; author reply 6277-8. PubMed ID: 16135504
    [No Abstract] [Full Text] [Related]

  • 37. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
    Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ.
    Cancer Res; 2004 Jul 15; 64(14):4849-57. PubMed ID: 15256455
    [Abstract] [Full Text] [Related]

  • 38. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 39. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
    Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B.
    Cancer Control; 2003 Dec 12; 10(4):297-305. PubMed ID: 12915808
    [Abstract] [Full Text] [Related]

  • 40. Role of Nucleotide Excision Repair in Cisplatin Resistance.
    Duan M, Ulibarri J, Liu KJ, Mao P.
    Int J Mol Sci; 2020 Dec 04; 21(23):. PubMed ID: 33291532
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.